PTC Therapeutics Q2 Revenue Beats Modestly, Sephience Outlook in Focus, Morgan Stanley Says

MT Newswires Live

Aug 08

PTC Therapeutics (PTCT) Q2 net product revenue and royalties came in modestly ahead of expectations, Morgan Stanley said in a Friday note.

Morgan Stanley added that PTC Therapeutics' unchanged 2025 revenue guidance reflected some uncertainty around the contribution from new product launches.

The lower end of the guidance contemplating rapid Emflaza genericization, while the higher end reflects successful new product approvals, including Sephience, a newly approved treatment for sepiapterin-responsive phenylketonuria.

On Thursday, PTC Therapeutics posted better-than-expected Q2 results and continued to expect 2025 revenue to be between $650 million and $800 million.

Morgan Stanley has a overweight rating on the company and raised its price target to $76 from $70 on Q2 results and updated Sephience assumptions following its recent approvals in the US and Europe.

Shares of PTC Therapeutics were down 7% in recent trading.

Price: 46.85, Change: -3.51, Percent Change: -6.97

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2558752035"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2558752035\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2558752035?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-08 23:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2558752035","market":"sh","top_or_hot":-1,"title":"PTC Therapeutics Q2 Revenue Beats Modestly, Sephience Outlook in Focus, Morgan Stanley Says","media":"MT Newswires Live","content":"<html><body><p> PTC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (PTCT) Q2 net product revenue and royalties came in modestly ahead of expectations, <a href=\"https://laohu8.com/S/MTK\">Morgan Stanley</a> said in a Friday note.</p><p>Morgan Stanley added that PTC Therapeutics' unchanged 2025 revenue guidance reflected some uncertainty around the contribution from new product launches.</p><p>The lower end of the guidance contemplating rapid Emflaza genericization, while the higher end reflects successful new product approvals, including Sephience, a newly approved treatment for sepiapterin-responsive phenylketonuria.</p><p>On Thursday, PTC Therapeutics posted better-than-expected Q2 results and continued to expect 2025 revenue to be between $650 million and $800 million.</p><p>Morgan Stanley has a overweight rating on the company and raised its price target to $76 from $70 on Q2 results and updated Sephience assumptions following its recent approvals in the US and Europe.</p><p>Shares of PTC Therapeutics were down 7% in recent trading.</p><p>Price: 46.85, Change: -3.51, Percent Change: -6.97</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PTC Therapeutics Q2 Revenue Beats Modestly, Sephience Outlook in Focus, Morgan Stanley Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPTC Therapeutics Q2 Revenue Beats Modestly, Sephience Outlook in Focus, Morgan Stanley Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-08-08 23:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> PTC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (PTCT) Q2 net product revenue and royalties came in modestly ahead of expectations, <a href=\"https://laohu8.com/S/MTK\">Morgan Stanley</a> said in a Friday note.</p><p>Morgan Stanley added that PTC Therapeutics' unchanged 2025 revenue guidance reflected some uncertainty around the contribution from new product launches.</p><p>The lower end of the guidance contemplating rapid Emflaza genericization, while the higher end reflects successful new product approvals, including Sephience, a newly approved treatment for sepiapterin-responsive phenylketonuria.</p><p>On Thursday, PTC Therapeutics posted better-than-expected Q2 results and continued to expect 2025 revenue to be between $650 million and $800 million.</p><p>Morgan Stanley has a overweight rating on the company and raised its price target to $76 from $70 on Q2 results and updated Sephience assumptions following its recent approvals in the US and Europe.</p><p>Shares of PTC Therapeutics were down 7% in recent trading.</p><p>Price: 46.85, Change: -3.51, Percent Change: -6.97</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PTC","symbol_name":"PTC Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2558752035","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2558752035","pubTimestamp":1754667814,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"PTC Therapeutics  Q2 net product revenue and royalties came in modestly ahead of expectations, Morgan Stanley said in a Friday note.Morgan Stanley added that PTC Therapeutics' unchanged 2025 revenue guidance reflected some uncertainty around the contribution from new product launches.The lower end of the guidance contemplating rapid Emflaza genericization, while the higher end reflects successful new product approvals, including Sephience, a newly approved treatment for sepiapterin-responsive phenylketonuria.On Thursday, PTC Therapeutics posted better-than-expected Q2 results and continued to expect 2025 revenue to be between $650 million and $800 million.Morgan Stanley has a overweight rating on the company and raised its price target to $76 from $70 on Q2 results and updated Sephience assumptions following its recent approvals in the US and Europe.Shares of PTC Therapeutics were down 7% in recent trading.Price: 46.85, Change: -3.51, Percent Change: -6.97","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"PTC":"PTC Inc.","PTCT":"PTC Therapeutics Inc."},"translate_title":"摩根士丹利表示，PTC Therapeutics第二季度收入小幅增长，Sefience前景成为焦点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PTC":1,"PTCT":1},"content_text":"PTC Therapeutics (PTCT) Q2 net product revenue and royalties came in modestly ahead of expectations, Morgan Stanley said in a Friday note.Morgan Stanley added that PTC Therapeutics' unchanged 2025 revenue guidance reflected some uncertainty around the contribution from new product launches.The lower end of the guidance contemplating rapid Emflaza genericization, while the higher end reflects successful new product approvals, including Sephience, a newly approved treatment for sepiapterin-responsive phenylketonuria.On Thursday, PTC Therapeutics posted better-than-expected Q2 results and continued to expect 2025 revenue to be between $650 million and $800 million.Morgan Stanley has a overweight rating on the company and raised its price target to $76 from $70 on Q2 results and updated Sephience assumptions following its recent approvals in the US and Europe.Shares of PTC Therapeutics were down 7% in recent trading.Price: 46.85, Change: -3.51, Percent Change: -6.97","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}